Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that President & CEO Renee D. Gala received an equity grant of 44,465 restricted stock units under the company’s 2011 Equity Incentive Plan. Each unit represents a right to receive one ordinary share when it vests.
The grant vests in four equal annual installments starting on March 5, 2026, with one-quarter vesting on the first anniversary of that date and the remaining three-quarters vesting in equal annual installments over the following three years. After this award, she directly holds 159,695 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Ted W. Love reported receiving a grant of 1,527 ordinary shares in the form of restricted stock units. The award was made at a price of $0.00 per share, reflecting an equity compensation grant rather than a market purchase.
Each restricted stock unit represents the right to receive one ordinary share if certain conditions are met. The units are scheduled to vest in full on July 24, 2026, subject to Dr. Love’s continuous service and additional plan conditions. Following this grant, he holds 1,527 ordinary shares directly.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported a mix of stock option exercises, share sales, and equity awards. She exercised multiple incentive and non-qualified stock options into ordinary shares and sold a total of 55,600 ordinary shares in open-market transactions at weighted average prices generally around $190–$193 per share. Patil also acquired 10,079 restricted stock units granted under the 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting on March 5, 2026. Following these transactions, she directly owns 58,818 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals senior vice president of Technical Operations Mary Elizabeth Henderson reported both an equity award and a share sale. She received 4,447 ordinary shares as a restricted stock unit grant at a price of $0.00 per share under the company’s 2011 Equity Incentive Plan. These units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting each year over four years. On the same date, she sold 5,343 ordinary shares in open-market transactions at a weighted average price of $194.4852 per share, in multiple trades between $194.1900 and $194.5000. According to the filing, these shares were sold to satisfy tax obligations arising from the vesting of previously granted restricted stock units, and she held 28,728 ordinary shares directly following the sale.
Form 144 notice filed related to proposed sales of common stock for JAZZ. The filing lists reported transactions by Patricia Carr: 1,253 shares sold on 02/26/2026 for $243,810 and 4,660 shares sold on 12/05/2025 for $797,783. The filing also lists issuer performance-share entries dated 01/16/2026.
ETRADE FINANCIAL CORPORATION reported a Form 144 notice to sell 2,370 performance shares dated 02/26/2026 as compensation. The filing lists Patricia Carr in prior activity, showing a sale of 4,660 common shares on 12/05/2025.
Jazz Pharmaceuticals submitted a Form 144 notice regarding proposed issuance/sale of restricted common stock as compensation. The filing lists 10,116 restricted common shares tied to 02/26/2026 and labels the transaction type as compensation.
The filing also reports a prior sale: Mary Elizabeth Henderson sold 2,238 common shares on 12/09/2025 for $379,365. The document otherwise provides standard Form 144 disclosure items for an issuer-related restricted stock transaction.
Jazz Pharmaceuticals plc describes a rare-disease focused biopharma business built around neurology and oncology therapies, anchored by its oxybate sleep franchise and epilepsy and cancer drugs. The company emphasizes Xywav and Epidiolex/Epidyolex as its largest products, with Xywav generating $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million of net product sales in 2025.
Oncology growth is led by Zepzelca, with $307.3 million of 2025 net sales, and newer launches Ziihera and Modeyso, both approved under FDA’s accelerated approval pathway for difficult-to-treat cancers. Rylaze adds another $402.9 million, and legacy Xyrem has declined to $146.0 million amid generic and authorized generic competition.
The report highlights revenue diversification away from high-sodium Xyrem, extensive global commercialization, and a deep pipeline including HER2-targeted antibody zanidatamab, additional Vyxeos studies, early-stage oncology assets JZP815 and JZP898, and expanded indications for Epidiolex. Jazz also underscores investment in R&D talent, scalable operations, and an inclusion-focused culture across roughly 2,890 employees.
Jazz Pharmaceuticals reported record 2025 total revenues of $4.27 billion, up 5%, with fourth-quarter revenue of $1.20 billion, up 10% year over year. Growth was driven by neuroscience and oncology franchises.
Flagship sleep drug Xywav generated $1.66 billion in 2025 sales, up 12%, while Epidiolex/Epidyolex reached $1.06 billion, up 9%. Oncology net product sales were $1.13 billion, up 2%, including launches of Modeyso and Ziihera.
Despite strong revenue, Jazz posted a 2025 GAAP net loss of $356 million, compared with $560 million net income in 2024, primarily due to $948 million of acquired in‑process R&D and litigation settlements. Non‑GAAP adjusted net income was $522 million. The company generated $1.36 billion of operating cash flow and guided 2026 revenue to $4.25–$4.50 billion.